Description

Simple

A medication used to improve the quality of images during a scan to see certain parts of the body, which is known as an MRI (or magnetic resonance imaging).

Clinical

A gadolinium compound used as a contrast agent in MRI tests of the brain, spine, and liver.

Overview

Gadoversetamide, marketed under the trade name OptiMARK, is a gadolinium compound used as a contrast agent in magnetic resonance imaging (MRI), particularly imaging of the brain, spine and liver.

Pharmacology

Indication

Gadoversetamide is an MRI contrast agent used for MRI diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors.

Pharmacodynamic

Information currently not available.

Mechanism of action

Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. MR images are based primarily on proton density and proton relaxation dynamics. MR instruments are sensitive to two different relaxation p... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

162 ± 25 mL/kg [normal subjects]

Clearance

72 +/- 16.3 mL/hr/kg [healthy]

Half life

Distribution 13.3 ± 6.8 (mean) minutes, elimination 103.6 ± 19.5 (mean) minutes.

Route of elimination

The mean cumulative urinary excretion of gadoversetamide at 72 hours was approximately 93.5% for renal impaired patients and 95.8% for subjects with normal renal function

Toxicity

Information currently not available.

Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Injection associated discomfort US
  • adult
  • Kind: experimental
    • Percent: 26%
  • Clinical Trial
    Headache US
    • adult
  • Kind: experimental
    • Percent: 9%
  • Clinical Trial
    Taste perversion US
    • adult
  • Kind: experimental
    • Percent: 6%
  • Clinical Trial
    Vasodilation US
    • adult
  • Kind: experimental
    • Percent: 6%
  • Clinical Trial
    Dizziness US
    • adult
  • Kind: experimental
    • Percent: 4%
  • Clinical Trial
    Nausea US
    • adult
  • Kind: experimental
    • Percent: 3%
  • Clinical Trial
    Abdominal Pain US
    • adult
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Asthenia US
    • adult
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Diarrhea US
    • adult
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Paresthesia US
    • adult
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Dyspepsia US
    • adult
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Back Pain US
    • adult
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Rhinitis US
    • adult
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Injection site reaction US
    • adult
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Parosmia US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Tinnitus US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Oliguria US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Anxiety US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Confusion US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Agitation US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Dystonia US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Diplopia US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Somnolence US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Hypertonia US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Hypesthesia US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Vertigo US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Cough US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Tremor US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Laryngismus US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Dyspnea US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Voice Alteration US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Sinusitis US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Pharyngitis US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Rash US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Pruritus US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Erythema multiforme US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Urticaria US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Thrombophlebitis US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Palpitation US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Syncope US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Tachycardia US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Hypotension US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Pallor US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Dry Mouth US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Dysphagia US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Vasospasm US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Anorexia US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Constipation US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Vomiting US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Edema US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial

    Contraindications

    • Route:
      • Intravenous
    • Hypersensitivity:
      • gadolinum
      • versetamide
    • Regions: US
    • Route:
      • Intravenous
    • Regions: US
    • Patient Conditions:
        • Name: Chronic, severe kidney disease
        • Drugbank Id: DBCOND0107818
        • Modification Of:
          • Base:
            • Name: Kidney Disease
            • Drugbank Id: DBCOND0027958
          • Severity:
            • Includes:
              • chronic
              • severe
    • Route:
      • Intravenous
    • Regions: US
    • Patient Conditions:
        • Name: Acute Kidney Injury
        • Drugbank Id: DBCOND0032980
        • Modification Of:
          • Base:
            • Name: Kidney Injury
            • Drugbank Id: DBCOND0039679
          • Severity:
            • Includes:
              • acute

    Food Interactions

    Information currently not available.